A spokesman for the State Food and Drug Administration (SFDA) said Thursday that improper production is probably the cause of the problematic antibiotic injection, which had allegedly led to 10 deaths in China.

The spokesman said the "Xinfu" antibiotic injection, manufactured by Anhui Huayuan Worldbest Biology Pharmacy Co., a subsidiary of Shanghai Worldbest Co. Ltd., was not produced in accordance with required technical procedures.

At a press conference on Thursday, the spokesman said the problematic drugs on market have been put under control.

He said that an investigation group has inspected the pharmacy company in east China's Anhui Province and checked the production procedures of the antibiotic injection produced during June and July of 2006.

The production records of company were found incomplete, said the spokesman, adding that more investigation in the link between patient reactions and the problematic medicine is underway.

(Xinhua News Agency August 10, 2006)